ClinicalTrials.gg
RecruitingNCT07339332Updated Jan 14, 2026

A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus

An Early Phase 1 interventional study of CAR-T Therapy in Systemic Lupus Erythematosus (SLE), sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — 8 open to participants now, 8 under way, none of them phase 3. Lupus Erythematosus, Systemic · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

Planned enrollment
6th of 11
12 · median 12
Started
2026
with 4 others
Phase 1
7 of 11
5 open now
Registered
7th of 11
by date

Among the 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, this one is the 6th largest by planned enrollment, is one of 5 that started in 2026, is one of 7 in phase 1, and was the 7th registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

8 of the 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, or all of them as a file.
02

Study summary

This study is a single arm, open, exploratory dose escalation clinical study to evaluate the safety, efficacy, and cellular metabolic dynamics of ct1195e cells in patients with SLE.

Read the detailed description

The study was divided into dose increasing stage and dose expanding stage.dose escalation phaseThree dose levels are tentatively determined for dose escalation: 3.0 × 108, 4.5 × 108 and 6.0 × 108 car-cd19/CD20+T cells. It is estimated that the target toxicity probability of the maximum tolerated dose is 30%, and about 12 participants are planned to be enrolled, and the number of enrolled patients in each dose group is subject to the actual situation. During the test, the researchers and partners will jointly negotiate whether to increase or decrease the dose, whether to increase to the set maximum dose group or produce the maximum available cell volume, and whether to increase the exploration of new dose level within the explored dose range (allowed to be conducted when the dose is increased or decreased) according to the participants' cell metabolism characteristics, safety, tolerance and preliminary effectiveness data, so as to determine the possible recommended therapeutic dose (RD).The DLT observation period is 28 days after the first infusion. If the treatment needs to be withdrawn before 28 days after the infusion due to disease progression or other reasons, no obvious car-t cell expansion is detected or car-t treatment is invalid, and the DLT related AE events determined by the researcher may not be related to the product, the DLT observation period can be completed before. During each dose increase, if there is a safety risk that needs to be discussed, the researchers and partners can make a dose increase/stability/decrease decision according to the safety and tolerance of participants and the metabolic kinetics of ct1192 cells. In the same dose group, the first participant had no significant safety risk 14 days after the completion of cell infusion, and subsequent participants could only carry out cell infusion.dose expansion phaseOne or more dose groups may be selected for dose expansion according to the results of the dose increasing stage to further explore the efficacy and safety in SLE patients. Each dose group and each queue plan to include up to 9 cases, and the specific number of patients in the group is subject to the actual number. DLT will not be observed in the dose expansion phase, and other research processes are the same as the dose increment phase. Researchers and collaborators will continue to monitor the safety data of the whole dose expansion phase and make decisions on admission and exit when necessary.

03

Conditions studied

  • Systemic Lupus Erythematosus (SLE)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary signing of Form (ICF): I fully understand and am informed of this study, and I have signed the Informed Consent Form, expressing my willingness to follow and complete all research procedures;
  • When signing the ICF, the age should be between 18 and 65 years old (inclusive), with no gender restrictions;
  • No systemic active infection (such as infectious pneumonia, tuberculosis) within 2 weeks before screening;
  • Females with fertility (defined as all females who are physiologically capable of becoming pregnant) must agree to use highly effective from at least 28 days before the start of self-cleaning to 1 year after CT1195E infusion, and absolutely prohibit egg donation within 1 year after receiving study treatment during the study period. Their male partners with fertility must agree to use effective barrier contraception from the start of self-cleaning to 1 year after CT1195E infusion, and should not donate semen or sperm during the entire study period;
  • Females with fertility must have a negative serum beta-human chorionic gonadotropin (β-hCG) test result at screening and within 48 hours prior to the initiation of chemotherapy.
  • Meet the EULAR/ACR 2019 classification criteria for SLE, with a disease history of ≥6 months;
  • Prior to screening, patients must have received treatment with combined with (including cyclophosphamide, mycophenolate mofetil, tacrolimus, methotrexate, cyclosporine, leflunomide) and/or biologics for ≥3 months, with a stable dosage for ≥2 weeks, and the disease must still be in an active state. During screening, oral steroids must meet the following requirements:

If treated with hormone therapy alone, prednisone (or equivalent medication) should be ≥7.5 mg/day; When used in combination with immunosuppressants and/or biologics, there is no minimum daily dosage requirement for steroids;

  • During screening, positive for antinuclear antibody, and/or positive for anti-ds-DNA antibody, and/or positive for anti-Smith antibody;
  • During the screening period, patients with a SLEDAI-2K score of ≥7, or those with concurrent significant organ dysfunction, such as severe immune-mediated thrombocytopenia, lupus nephritis ( diagnosed as active nephritis type III or IV with or without type V);
  • During screening, involvement of active organs (including kidneys, heart and lungs, musculoskeletal system, blood system, blood vessels, etc.; involvement of skin and mucous membranes alone is not included) is present;
  • Adequate organ function:

    1. Renal function: defined as rate (Cockcroft-Gault) calculated without hydration assistance ≥ 50 mL/min;
    2. Bone marrow function: defined as (ANC) ≥1.0×10\^9/L and (Hb) ≥60 g/L. During the 7 days prior to screening for inclusion and exclusion criteria, blood transfusions and growth factors must not be used to meet these requirements;
    3. Liver function: defined as (ALT) and aspartate aminotransferase (AST) levels ≤2× (ULN), and total levels ≤2× upper limit of normal (ULN)
    4. Coagulation function: defined as an (INR) or activated partial thromboplastin time (APTT) ≤1.5×ULN;
    5. Lung function: When exposed to indoor air, the blood oxygen saturation (SpO2) is ≥92% (measured by a pulse oximeter);
    6. Cardiac function: defined as having a (LVEF) of ≥50% as assessed by echocardiography (ECHO) within the 8 weeks prior to screening.

Exclusion criteria

Exclusion Criteria:

  • Those who have suffered from severe lupus nephritis within the previous 2 months and require hemodialysis, or have received prednisone ≥100 mg/d or equivalent hormone treatment for ≥14 days;
  • Those who have undergone plasma exchange, plasma separation, hemodialysis within the previous 30 days, or those who have suffered from lupus crisis within the previous 30 days;
  • Screen for individuals with a history of ≥ Grade 2 bleeding within the previous 30 days or those requiring long-term anticoagulant therapy;
  • History of any of the following cardiovascular diseases within 30 days prior to screening: heart failure of class III or IV, myocardial infarction, unstable angina, uncontrolled or symptomatic atrial arrhythmias, any ventricular arrhythmias, or other heart diseases;
  • Before screening, there were manifestations of the central nervous system caused by lupus, including but not limited to lupus headache, seizures, cognitive impairment, impaired intellectual function, and visual impairment;
  • Individuals with central nervous system diseases prior to screening include, but are not limited to: cerebrovascular accident, encephalitis, epilepsy, convulsion/seizure, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, central nervous system vasculitis, cognitive dysfunction, brain organic syndrome, or psychosis;
  • Screen for the absence of systemic active infections within the previous 2 weeks, including but not limited to active tuberculosis;
  • Previous exposure to CAR-T cell therapy or other gene-modified T cell therapies, or a history of major organ transplantation (such as heart, lung, kidney, liver) or hematopoietic stem cell/bone marrow transplantation;
  • Allergic or intolerant to diuretics, tocilizumab, or experiencing life-threatening allergic reactions, reactions, or intolerance to CT1195E formulation or its (including dimethyl sulfoxide (DMSO)), or having a history of other severe allergies such as anaphylactic shock;
  • Screen for individuals who have used targeted B-cell drugs such as rituximab within the previous 3 months;
  • Exclusion criteria: Subjects who have used other biologics such as TACI-Ig and Benlysta within the previous 12 weeks;
  • Within 2 weeks prior to the infusion of CT1195E, the use of prednisone (or equivalent drugs) at a dosage of ≥10 mg/day is allowed. Physiological substitutes, topical, and inhaled are also permitted;
  • Received T-cell-affecting (mycophenolate mofetil, methotrexate, cyclosporine, azathioprine, leflunomide, tacrolimus) within 2 weeks before infusion of CT1195E;
  • Have received JAK inhibitors (such as tofacitinib, baricitinib, ruxolitinib, etc.) within 2 weeks before the infusion of CT1195E;
  • Have received attenuated , inactivated vaccine, or RNA vaccine within one month before screening;
  • Suffered from malignant tumor within 2 years before signing the ICF. The following conditions are excluded: non-melanoma skin cancer that has undergone radical treatment, localized prostate cancer, -confirmed cervical carcinoma in situ or squamous intraepithelial lesion detected by cervical smear, and completely resected breast carcinoma in situ;
  • The participant has undergone major surgery within 4 weeks prior to signing the form, or plans to undergo major surgery during the study period, and the investigator believes that this would pose an unacceptable risk to the study participant;
  • During screening, there is evidence of , syphilis infection, active virus infection (HBsAg positive and HBV-DNA above the detection limit), or active virus infection (both HCV antibody and HCV-RNA positive);
  • Those who participated in other clinical studies within the previous three months or are still within the five half-lives after the last dose;
  • Concurrent major chronic diseases that are not under control and that the investigator believes may increase the risk to study participants;
  • Subjects with a history or evidence of suicidal thoughts within the previous 6 months, or any suicidal behavior within the previous 12 months, are considered by the researchers to have a significant risk of suicide;
  • Pregnant or lactating women;
  • The researcher judges that the study participant has poor compliance, is unable or unwilling to adhere to the requirements of the study protocol, or has other reasons that make them unsuitable for participating in this clinical study.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    CT1195E CAR-T cells Injection

    CT1195E cells infusion

    Other: CAR-T Therapy

Interventions

  • OtherCAR-T Therapy

    CT1195E cells infusion

06

What researchers measure

Primary outcomes

  1. severity of dose limiting toxicity (DLT)

    Time frame: Within 28 days after infusion

  2. Incidence of dose limiting toxicity (DLT)

    Time frame: Within 28 days after infusion

  3. Evaluate the maximum tolerable dose (MTD) and/or dose range of ct1195E

    Ct1195E MTD and/or dose range

    Time frame: After medication to day 28

  4. severity of adverse events (AES)

    Time frame: Within 180 days after infusion

  5. Incidence of adverse events (AES)

    Time frame: Within 180 days after infusion

Secondary outcomes

  1. Proportion of participants with SLE responder index (sri-4)

    Preliminary evaluation of the efficacy of ct1195E in the treatment of moderate to severe refractory SLE.Proportion of participants who reached SLE responder index (sri-4) at 6 months and other time points (1, 2,3, 9 and 12 months after medication)

    Time frame: 1, 2,3, 6, 9 and 12 months after drug use

  2. Proportion of participants with low lupus disease activity status (lldas)

    To evaluate the efficacy of ct1195E in the treatment of moderate to severe refractory SLE. The proportion of participants who reached lupus low disease activity status (lldas) at 6 months and other time points (1, 2, 3, 9 and 12 months after medication).

    Time frame: 1, 2,3, 6, 9 and 12 months after drug use

  3. Proportion of participants achieving disease remission (doris)

    To evaluate the efficacy of ct1195E in the treatment of moderate to severe refractory SLE. The proportion of participants who achieved disease remission (doris) at 6 months and other time points ((1, 2, 3, 9 and 12 months after medication).

    Time frame: 1, 2, 3, 6, 9 and 12 months after drug use

  4. Changes of SLE disease activity index (sledai-2k) score from baseline after medication

    The score range of the Health Assessment Questionnaire Disability Index (HAQ-DI) is usually 0 to 3, where 0 represents no disability or intact function, and 3 represents severe disability or complete loss of function. The higher the score, the worse the functional status of the patient, that is, the higher the degree of disability; Conversely, the lower the score, the better the function.

    Time frame: 1,2,3,6,9 and 12 months after drug use

  5. After treatment, the SLE disease activity index (Selena - SLEDAI) score changed from baseline

    The minimum value of selena-sledai score is 0 points, and the maximum value can reach 105 points theoretically, but in actual clinical practice, 10 to 15 points usually indicate the presence of disease activity. Higher scores indicate higher disease activity rather than better outcomes. The score is used to quantify the activity of systemic lupus erythematosus (SLE). An increase in the score reflects a more active condition, which requires active clinical intervention; Conversely, a reduced score indicates good disease control.

    Time frame: 1, 2, 3, 6, 9 and 12 months after drug use

  6. After treatment, the index of lupus erythematosus assessment group (bilag-2004) changed from baseline

    The minimum value of the British Isle lupus rating group index (bilag-2004) is 0 and the maximum value is 100. The higher the score, the higher the disease activity, that is, the more serious the disease.

    Time frame: 1, 2, 3, 9 and 12 months after drug use

  7. The SLE activity score (sle-das) changed from baseline after treatment

    The minimum value of sle-das score (systemic lupus erythematosus disease activity score) is 0, and the maximum value is usually 100. This score quantifies the disease activity by accumulating the scores of clinical and laboratory indicators. The higher the score, the stronger the disease activity and the more serious the disease.

    Time frame: 1, 2, 3, 9 and 12 months after drug use

  8. Changes in clinicians' overall judgment (PGA) score from baseline after medication

    In systemic lupus erythematosus (SLE), the minimum value of the doctors' global assessment (PGA) score is 0, and the maximum value is 3, where 0 indicates no disease activity and 3 indicates the most serious disease activity. The higher the score, the higher the disease activity, that is, the worse the result; Conversely, the lower the score, the lower the disease activity, and the better the result.

    Time frame: 1, 2, 3, 9 and 12 months after drug use

  9. Proportion of patients without other SLE therapy after medication

    Time frame: 1, 2, 3, 9 and 12 months after drug use

  10. Changes in immunoglobulin (IgG, IgM, IgA) levels during medication

    Time frame: 1, 2, 3, 9 and 12 months after drug use

  11. The change value of post medication Health Assessment Questionnaire Disability Index (HAQ-DI) from baseline

    The minimum possible score of patients with systemic lupus erythematosus (SLE) using the Health Assessment Questionnaire Disability Index (HAQ-DI) is 0, and the maximum possible score is 3; The higher the score, the more severe the dysfunction of the patient, that is, the worse the outcome.

    Time frame: 1, 2, 3, 9 and 12 months after drug use

  12. duration of ct1195E gene in blood

    Objective to evaluate the cell kinetics of ct1195E in SLE participants, and to observe the level and duration of ct1195E gene copy number in blood.

    Time frame: Within 1 year after CAR-T cell infusion

  13. Copy numbe of ct1195E gene in blood

    Objective to evaluate the cell kinetics of ct1195E in SLE participants, and to observe the level and duration of ct1195E gene copy number in blood.

    Time frame: Within 1 year after CAR-T cell infusion

  14. Changes of B cell functional subsets (initial B cells, memory B cells, plasma cells) after ct1195E infusion

    Evaluate the efficacy (PD) characteristics of CT1195E in SLE participants. Changes in the levels of B cell functional subgroups (initial B cells, memory B cells, plasma cells) after CT1195E infusion.

    Time frame: Within 1 year after CAR-T cell infusion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Jun 2027, 17 months later.

Of 147 phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 36. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Jan 14, 2026
StartEst.
Jan 16, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07339332
Collaborators
CARsgen Therapeutics Co., Ltd.
Responsible party
Qiubai Li (Director, Head of Department of Rheumatology and Immunology, Principal Investigator, Professor, Wuhan Union Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology) — Principal investigator
First posted
Jan 14, 2026
Start date
Jan 16, 2026 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jan 14, 2026

Study contacts

Qiubai Li
Contact
qiubaili@hust.edu.cn
Professor 85726808 Ext.027

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion